Abstract
Birch pollen is the major allergen in pollinosis in northern Japan. IgE reactivity to individual birch pollen allergens has been shown to differ between populations of birch pollen-allergic patients living in different countries. In this study, we examined the IgE profiles to recombinant birch pollen allergens in birch-sensitive patients living in Sapporo. This study used the sera of 40 patients with specific IgE toward birch pollen extract. Their sera were analyzed for specific IgE reactivity to individual birch pollen allergens (recombinant Bet v 1, Bet v 2 and Bet v 4) and natural birch pollen extract using Pharmacia CAP SystemTM. Of 40 sera with positive CAP results for natural birch pollen extract, 39 (97.5%) had specific IgE towards Bet v 1; 6 (15%) contained specific IgE against Bet v 2. Bet v 4 reactivity was documented in only one subject (2.5%). The present data suggest that the specific IgE reactivity profiles to birch pollen allergen in birch-sensitive patients in Sapporo correspond to those in Scandinavia, possibly due to the heavy birch pollen exposure in this area. This observation provides useful information for future birch allergen-specific immunotherapy in Japan.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call